Trial Profile
LIBERTY 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Estradiol/norethisterone (Primary) ; Relugolix (Primary)
- Indications Uterine leiomyoma
- Focus Registrational; Therapeutic Use
- Acronyms LIBERTY 2
- Sponsors Myovant Sciences
- 17 Aug 2023 Results of post-hoc subgroup analysis assessing the safety and efficacy of relugolix-combination therapy in European women from pivotal trials (LIBERTY 1 and LIBERTY 2) published in the Gynecological Endocrinology.
- 09 Nov 2022 Results of a pooled analysis from two clinical studies (LIBERTY 1 and LIBERTY 2) assessing effect of relugolix combination therapy on symptom burden and health-related quality of life in women with uterine fibroids published in the American Journal of Obstetrics and Gynecology
- 03 Nov 2022 Results of pooled analysis (NCT03049735; NCT03103087; NCT03412890) assessing the long-term efficacy and safety of relugolix combination therapy treatment for up to 52 weeks published in the Obstetrics and Gynecology